Amyris Inc. (NASDAQ:AMRS) major shareholder (Mauritius) Pte Ltd Maxwell sold 2,300,000 shares of the company’s stock in a transaction dated Monday, October 17th. The stock was sold at an average price of $0.83, for a total transaction of $1,909,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Amyris Inc. (NASDAQ:AMRS) opened at 1.08 on Wednesday. The company’s market cap is $253.82 million. The firm’s 50-day moving average is $0.55 and its 200 day moving average is $0.59. Amyris Inc. has a 1-year low of $0.31 and a 1-year high of $1.85.

Amyris (NASDAQ:AMRS) last released its earnings results on Thursday, August 4th. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.06. The business earned $9.60 million during the quarter, compared to analysts’ expectations of $15.23 million. During the same quarter in the previous year, the business earned ($0.47) EPS. The business’s revenue for the quarter was up 23.1% on a year-over-year basis. Analysts predict that Amyris Inc. will post ($0.20) earnings per share for the current fiscal year.

A number of brokerages recently issued reports on AMRS. Zacks Investment Research cut shares of Amyris from a “buy” rating to a “hold” rating in a research note on Monday, September 5th. Singular Research reiterated a “buy” rating and issued a $2.80 price target on shares of Amyris in a research note on Wednesday, September 28th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $2.66.

A number of hedge funds have recently added to or reduced their stakes in the company. Jacobs Levy Equity Management Inc. acquired a new stake in Amyris during the first quarter worth $269,000. Geode Capital Management LLC raised its position in shares of Amyris by 11.6% in the first quarter. Geode Capital Management LLC now owns 298,669 shares of the company’s stock valued at $331,000 after buying an additional 30,958 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Amyris by 22.4% in the second quarter. Vanguard Group Inc. now owns 1,701,779 shares of the company’s stock valued at $766,000 after buying an additional 311,142 shares in the last quarter. Institutional investors and hedge funds own 35.68% of the company’s stock.

About Amyris

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

5 Day Chart for NASDAQ:AMRS

Receive News & Stock Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related stocks with our FREE daily email newsletter.